Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to -$50.4 million.

  • Rocket Pharmaceuticals' Cash from Operations rose 323.01% to -$50.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$202.1 million, marking a year-over-year decrease of 520.25%. This contributed to the annual value of -$209.7 million for FY2024, which is 759.71% down from last year.
  • Latest data reveals that Rocket Pharmaceuticals reported Cash from Operations of -$50.4 million as of Q3 2025, which was up 323.01% from -$49.0 million recorded in Q2 2025.
  • Rocket Pharmaceuticals' 5-year Cash from Operations high stood at -$24.3 million for Q1 2021, and its period low was -$57.6 million during Q1 2023.
  • Moreover, its 5-year median value for Cash from Operations was -$49.0 million (2025), whereas its average is -$45.2 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first tumbled by 13602.87% in 2021, then soared by 4762.86% in 2023.
  • Over the past 5 years, Rocket Pharmaceuticals' Cash from Operations (Quarter) stood at -$30.9 million in 2021, then crashed by 81.06% to -$56.0 million in 2022, then soared by 47.63% to -$29.3 million in 2023, then plummeted by 60.0% to -$46.9 million in 2024, then fell by 7.41% to -$50.4 million in 2025.
  • Its Cash from Operations stands at -$50.4 million for Q3 2025, versus -$49.0 million for Q2 2025 and -$55.8 million for Q1 2025.